Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when HIMS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NYSE: HIMS Hims & Hers Health, Inc. 8-K

Hims & Hers establishes $400M receivables purchase facility with JPMorgan

Filed July 1, 2026 · Period ending June 26, 2026 · ~1 min read

4 key changes 1 high relevance 1 section

Key Changes

  • high

    Two HIMS subsidiaries entered a $400M receivables purchase facility with JPMorgan, allowing them to sell eligible receivables at a discount for immediate cash. JPMorgan retains discretion to decline purchases. Initial 364-day term with indefinite one-year extension options.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • medium

    HIMS guaranteed its subsidiaries will perform their obligations under the facility but explicitly did not guarantee receivables collectability or subsidiary creditworthiness, limiting parent exposure to operational performance rather than credit risk.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • medium

    HIMS amended its existing revolving credit agreement to permit the receivables facility and carved out a $400M basket for related indebtedness. Interest rates, fees, covenants, and default provisions remain otherwise unchanged.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • medium

    The receivables purchase facility is reported as a direct financial obligation under Item 2.03, signaling creation of a new balance-sheet liability alongside the agreement disclosure.

    Item 2.03 — Creation of a Direct Financial Obligation verify on EDGAR →

Summary

Hims & Hers Health established a $400 million receivables purchase facility through two subsidiaries, XeCare and Apostrophe Pharmacy, with JPMorgan as purchaser. The facility allows the subsidiaries to sell eligible customer receivables at a discount for immediate cash, providing a new liquidity tool to accelerate collections.

JPMorgan retains full discretion to decline purchases, and the facility runs for 364 days with indefinite one-year extension options by mutual agreement. The parent company guaranteed its subsidiaries will perform their obligations under the facility but explicitly excluded guarantees of receivables collectability or subsidiary creditworthiness.

This structure limits HIMS's exposure to operational performance rather than underlying credit risk on the receivables sold. To accommodate the new facility, HIMS amended its existing revolving credit agreement to carve out a $400 million basket for related indebtedness and made conforming changes to lien and collateral provisions, while leaving interest rates, fees, covenants, and default terms unchanged. For retail holders, this facility represents a working-capital management tool that can smooth cash flow by monetizing receivables before customers pay. The structure is common in healthcare and subscription businesses with predictable payment streams. The parent guarantee is narrowly scoped, and the facility's discretionary nature means JPMorgan bears the credit risk on purchased receivables.

Section-by-Section Diff

Event · Item 2.03 — Creation of a Direct Financial Obligation

~44 words

Item 2.03 also reports this as a direct financial obligation (body incorporates the primary Item by reference).

1 Added
Added Item 2.03 — direct financial obligation (cross-ref) medium

Added in current filing · verify on EDGAR →

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information described above under Item 1.01 is incorporated into this Item 2.03 by reference.

The 8-K includes a labeled Item 2.03 section. Its body incorporates the primary Item (typically 1.01) by reference rather than restating terms — do not treat that thinness as 'Item 2.03 absent.' The company is signaling creation of a direct financial obligation alongside the agreement disclosure; keep Item 2.03 visible in the report.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jul 20, 2026 · How we verify